Daré Bioscience, Inc. / Fundamentals
Income statement
- Net revenue
-€15.28K - Cost of goods sold
€274.27K - Gross profit
-€12.29M - SG&A expenses
€7.53M - R&D expenses
€8.37M - EBITDA
-€15.40M - D&A
€547.42K - EBIT
-€15.95M - Interest expenses
€231.75K - EBT
-€16.06M - Tax expenses
€0.00 - Net income
-€16.06M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€622.07K - Changes in working capital
€4.83M - Operating cash flow
-€10.00M - Capex
€245.50K - Other investing cash flow
€0.00 - Net investing cash flow
-€245.50K - Total cash dividends paid
€0.00 - Issuance of common stock
€834.34K - Debt repayment
-€234.43K - Other financing cash flow
-€162.17K - Net financing cash flow
€437.74K - Foreign exchange effects
-€58.52M - Net change in cash
-€9.82M - Cash at end of period
€4.60M - Free cash flow
-€9.75M
Balance sheet
- Cash and cash equivalents
€4.35M - Cash and short-term investments
€4.35M - Total receivables
€162.35K - Inventory
€0.00 - Other current assets
€1.19M - Total current assets
€5.70M - Property, plant & equipment
€4.58M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€258.91K - Other non-current assets
€664.45K - Total non-current assets
€5.50M - Total assets
€11.20M - Accounts payable
€1.52M - Short-term debt
€2.09M - Other current liabilities
€2.34M - Total current liabilities
€16.59M - Long-term debt
€4.74M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€5.60M - Total liabilities
€22.19M - Common stock
€779.32 - Retained earnings
-€158.53M - Other equity
-€347.65K - Total equity
-€10.99M - Total liabilities and shareholders' equity
€11.20M
Company information
- Market capitalization
€17.85M - Employees
21 - Enterprise Value
€22.01M
Company ratios
- Gross margin
-
80,447.7% Much worse than peer group: 1,607,496,741,822,598,600.0% - EBITDA margin
-
100,812.0% Much worse than peer group: 25,816,577,038,758,220,000.0% - EBIT margin
-
104,388.5% Much worse than peer group: 21,553,324,037,667,667,000.0% - EBT margin
-
105,098.5% Much worse than peer group: 25,726,990,443,671,264,000.0% - Net margin
-
105,098.5% Much worse than peer group: 29,454,181,604,404,540,000.0% - ROE
-
146.1% Much better than peer group: -148.3% - ROA
-
-143.3% Much worse than peer group: -114.1% - Asset turnover
-
-0.1% Worse than peer group: 12.4% - FCF margin
-
67,058.0% Much worse than peer group: 29,122,095,576,669,300,000.0% - FCF yield
-57.4% - Efficiency ratio
-100,712.0% - Net sales per employee
-
-€727.46 - Net income per employee
-
-€764.55K